Biologics are more effective at treating adult-onset Still’s disease (AOSD) than are glucocorticoids or conventional disease-modifying antirheumatic drugs (DMARDs), according to a new retrospective ...

Patients with rheumatoid arthritis (RA) whose symptoms improved after they started taking nonbiologic disease-modifying antirheumatic drugs (DMARDs) also demonstrated restored balance in their oral ...

About one-third of patients prefer in-hospital administration, particularly if they are older or already make frequent visits to the hospital. Most patients with rheumatoid arthritis (RA) would prefer ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

Still's disease is an unusual form of arthritis that, in children, is also called systemic juvenile idiopathic arthritis, but it can also develop in adults. Few rigorous studies have examined biologic ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this 12-part journey ...

Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes ...

There’s no cure for rheumatoid arthritis (RA), but early treatment with disease-modifying antirheumatic drugs (DMARDs) may push symptoms into remission and slow disease progression. Treatment options ...

Objectives Treatment of rheumatoid arthritis (RA) relies on immunomodulatory drugs that can compromise immunity, inducing secondary immunodeficiency (SID). However, features of SID, such as ...